AstraZeneca announces a 7% revenue increase to $13.6 billion in Q1 2025, with product sales up by 6% and core operating profit growing by 12%. The company forecasts continued growt...
AstraZeneca PLC announced a 7% revenue increase to $13.6 billion in Q1 2025, with product sales up by 6%. The company forecasts continued growth, aiming for $80 billion in total re...
AstraZeneca announces a 7% revenue increase to $13.6 billion in Q1 2025, with product sales up by 6% to $12.9 billion. The company forecasts continued growth, aiming for $80 billio...
AstraZeneca announces a 7% revenue growth to $13.6 billion in Q1 2025, with product sales up by 6% and core operating profit increasing by 12%. The company forecasts continued grow...
AstraZeneca PLC has announced a 7% increase in Q1 revenue for 2025, reaching $13.6 billion, showcasing its strong performance in the pharmaceutical industry.
AstraZeneca announces a $2.5 billion investment in Beijing to establish a new R&D center, aiming to enhance its global research capabilities and strengthen its commitment to China'...
AstraZeneca announces a $2.5 billion investment to establish a strategic R&D center in Beijing, marking its second in China and sixth worldwide. This move highlights the company's ...
AstraZeneca announces a $2.5 billion investment to establish its second R&D center in Beijing, aiming to employ 1,700 personnel. The initiative includes partnerships with Beijing's...
AstraZeneca announces a $1 billion acquisition of EsoBiotec SA, aiming to enhance its biotech portfolio and advance innovative cell therapies globally. The deal, expected to close ...
AstraZeneca plc has announced a definitive agreement to acquire EsoBiotec SA for up to $1 billion, aiming to advance innovative drug development and expand its biotech presence. Th...
AstraZeneca has scrapped plans for a vaccine plant near Liverpool after failing to agree on government funding. The move highlights challenges in UK's vaccine production ambitions,...
AstraZeneca and Daiichi Sankyo withdraw their EU marketing authorization application for datopotamab deruxtecan due to mixed trial results, but remain committed to ongoing research...
